Pinsent Masons advises medtech startup OASYS NOW as it reaches significant milestone

Founded in 2021 by Nima Salami, a Cybersecurity and AI Computer Scientist, and Sara Okhuijsen, a Bioinformatician and Genomic Privacy Researcher, OASYS NOW is an AI-powered health data platform built to help researchers capitalise on the latest breakthroughs in technology and science to improve precision medicine and preventative healthcare.

In its fourth year of operation, OASYS NOW’s ambitious journey has culminated in a prestigious Slush 100 win, achieving recognition for its innovation from a jury of technology and venture capital industry experts. A milestone achievement, the prize entailed a €‎1 million investment – the startup’s first – from leading early-stage funds General Catalyst and Cherry Ventures, who will also offer coveted advice on achieving growth and scale.

Led by the Amsterdam TMT team, Pinsent Masons began working with OASYS NOW shortly after its inception, with Legal Director Data Law Andre Walter serving also as board advisor. Andre is supported by a broader international and cross-practice team, including Head of TMT Netherlands, Wouter Seinen and Head of IP Germany, Nils Rauer. This team has provided ongoing legal advice for all complex regulatory and legislative changes impacting cross-border data compliance under GDPR and the EU AI Act, in addition to key intellectual property considerations.

Commenting on OASYS NOW’s journey, Andre Walter said: “It has been a privilege to support Nima and his team as they’ve revolutionised AI-powered clinical trial management and worked at exceptional pace to build a platform capable of providing researchers with fully compliant genetic data. Their recognition at Slush 2024 reflects how transformative this pioneering approach will be in the MedTech field, and we look forward to continuing to advise Nima and his team as they capitalise on the next chapter of their growth."

On OASYS NOW’s Slush 100 win, Co-founder and CEO Nima Salami said: “Since 2021, our team has been working to address gaps in data provision for clinical trials. Before we entered the market, around 80 per cent of trials failed to meet the initial enrollment target and timeline, costing pharmaceutical companies as much as $8 million per day- a cost which our technology mitigates. The Pinsent Masons team has been invaluable in supporting our progress to achieving this outcome, not only in ensuring we stay ahead of new legislation but also in devising innovative legal solutions to logistical challenges."

Sara Okhuijsen, CTO & Co-founder of OASYS NOW, added: “With the investment from General Catalyst and Cherry Ventures, we look forward to distributing our AI-powered clinical trial management software and building on the success of our latest invention, Confidential Federated Learning. This technology- which has won recognition from the European Lighthouse on Secure and Safe AI (ELSA) - enables the discovery of unique biomarkers, paving the way for research and development of ground breaking personalized medicine for rare genetic diseases, all while offering compliant- and privacy-by-design solutions to researchers worldwide."